Navigation Links
Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Apr 16, 2007 - Amgen (Nasdaq:AMGN) today presented the results from a randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of Aranesp(R) (darbepoetin alfa) for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy ("the 103 study"). Aranesp is not approved for use by the FDA or EMEA in these patients. These results were presented in an oral session at the 2007 American Association for Cancer Research (AACR) annual meeting in Los Angeles, Calif. (AACR Abstract #LB-3).

As reported in January, the study did not meet its primary endpoint of reducing red blood cell (RBC) transfusions in the Aranesp treatment group. Transfusion occurrences from weeks 5 to 17 favored Aranesp but were not statistically significant between the groups (hazard ratio: 0.85, p=0.32). Among those receiving Aranesp, there was a significantly higher proportion of patients with a hemoglobin response (p less than 0.0001), hemoglobin correction (p less than 0.001), and hematopoietic response (p=0.002) compared with placebo.

The adverse event rate was similar between the groups. However, the overall number of deaths was greater in the Aranesp group (48.5 percent versus 46 percent in placebo; hazard ratio: 1.29; p=0.006). In post-hoc analyses adjusting for stratification factors at randomization and sex, stage IV disease, prior chemotherapy use and prior radiotherapy use, there remained a significant difference in survival between the groups. However, hazard ratios and statistical significance diminished when the analyses were further adjusted for known prognostic factors including baseline ECOG status, tumor type, tumor stage, baseline FACT-F cutoff at median and baseline Hb (hazard ratio: 1.17, p=0.11).

"This study evaluated ESA treatment for patients with active cancer, not receiving chemotherapy or radiation
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Aranesp ``145 Study Shows No Difference in Survival in Patients with Small-Cell Lung Cancer
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:8/29/2014)... Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... Global Healthcare Conference on Wednesday, September 10. ... Officer, will provide an update on the company, beginning ... Daylight Time).   A webcast of the ...
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
(Date:8/29/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) ... District of New Jersey has ... Sandoz, Inc. regarding United Therapeutics, Remodulin ® product.  In ... U.S. Patent No. 6,765,117 is both valid and enforceable ... generic product until the expiration of that patent in ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2
(Date:8/30/2014)... 30, 2014 In today’s world, a ... difficult to get. Snoring and sleep apnea (a medical ... stops) robs people and their bed partners of the ... to 45% of the population snores and 20 million ... Of these, only 10% have been diagnosed and treated; ...
(Date:8/30/2014)... 30, 2014 Top10BestSEOHosting.com is a ... have announced that HostGator.com http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts is ... market. Also, they has announced that Bluehost and ... , Hostgator, one of the Top 10 Web ... cheap Windows hosting, and it offers rich features ...
(Date:8/30/2014)... Delhi, India (PRWEB) August 30, 2014 ... online reputation management industry, has announced to offer guarantee ... has decided to offer this guarantee because of its ... more than 200 clients from all over the world ... doing extremely good job. , On being asked ...
(Date:8/30/2014)... LiveStreamingFitness.com, a company dedicated to providing live at home fitness ... to announce it has been recognized as one of the ... ABC’s Good Morning America. , As aired ... “Live Streaming Fitness is the hottest new trend in fitness. ... workout…to boot camp at Life Streaming Fitness for less than ...
(Date:8/30/2014)... AZ (PRWEB) August 30, 2014 Jake W., ... School while in the Back2Basics Outdoor Adventures transition ... to finish high school so I can actually start on ... English and math, and I'm done.” , He has six ... initial Back2Basics program. Most clients choose to continue on to ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Top10BestSEOHosting.com: HostGator.com Is The Best Windows Hosting Supplier 2Health News:Removecomplaints.net Announces Guaranteed Complaints Removal Services 2Health News:LiveStreamingFitness.com is New Trend In Fitness 2
... , MASON, Ohio, Aug. 10 ... physicians representing the Women,s Dermatologic Society (WDS) will provide ... enjoying the Western & Southern Financial Group Master,s and Women,s ... a.m.-5:00 p.m. Led by board-certified dermatologist Allison Moosally, MD (Cleveland), ...
... PHILADELPHIA, August 10 , ... of System,s,Nine-Year "Journey to Excellence"; Elsevier Becomes Primary Information,Source ... http://www.elsevier.com ), a world leader in healthcare and,medical publishing ... of the top 10 Catholic health systems in the ...
... August 10 , - ... Help,Prevent Costly Mistakes; Hospitals Benefit From Averting the Reimbursement,Losses ... in healthcare and medical publishing and online,solutions, today announced ... Consult designed to help nurses prevent the 10 "Never ...
... ... US Drug Watchdog is intensifying its national efforts to get the word out ... Remedy Swabs. According to the group, "Our reasons are pretty simple. We fear ... has said, use of the products could result in a loss of taste, ...
... ... ... Tucson, Arizona is home to a dense Hispanic population. In recognition of September 15th ... word throughout the local Hispanic community that colorectal pre-screening can save lives., , , ...
... ... the publicly available iHOP database enables researchers to quickly and effectively use this invaluable ... ... of a new tutorial suite for iHOP, or Information Hyperlinked Over Proteins. iHOP ...
Cached Medicine News:Health News:Ohio Dermatologists to Help Tennis Community Get Into the Swing of Sun Safety 2Health News:CHRISTUS Health Selects Five Elsevier Clinical Decision Support Solutions to Transform Care Delivery for Patients, Physicians, Nurses and Pharmacists 2Health News:CHRISTUS Health Selects Five Elsevier Clinical Decision Support Solutions to Transform Care Delivery for Patients, Physicians, Nurses and Pharmacists 3Health News:CHRISTUS Health Selects Five Elsevier Clinical Decision Support Solutions to Transform Care Delivery for Patients, Physicians, Nurses and Pharmacists 4Health News:Nurses to Benefit From New CMS Never Events Resource Area on Mosby's Nursing Consult 2Health News:Nurses to Benefit From New CMS Never Events Resource Area on Mosby's Nursing Consult 3Health News:Nurses to Benefit From New CMS Never Events Resource Area on Mosby's Nursing Consult 4Health News:The US Drug Watchdog Calls Zicam Nasal Gel Or Zicam Swabs A National Disaster That May Have Caused People To Lose Their Sense Of Smell 2Health News:Hispanics at High Risk for Colorectal Cancer 2Health News:Hispanics at High Risk for Colorectal Cancer 3Health News:New Online Tutorial for iHOP from OpenHelix 2Health News:New Online Tutorial for iHOP from OpenHelix 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: